Active, not recruitingPhase 3NCT06033586
Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
Studying Polycythemia vera
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Protagonist Therapeutics, Inc.
- Intervention
- Open-label rusfertide(drug)
- Enrollment
- 46 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (1)
- Pontchartrain Cancer Care, Covington, Louisiana, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06033586 on ClinicalTrials.govOther trials for Polycythemia vera
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07362225MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)MPN Research Foundation
- RECRUITINGPHASE2NCT07232290Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia VeraChengdu Zenitar Biomedical Technology Co., Ltd
- RECRUITINGPHASE2NCT06985147A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)Disc Medicine, Inc
- RECRUITINGNCT06743035Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic SplenomegalyiOMEDICO AG
- RECRUITINGNCT06752941LOW-PV ContinuationFROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- RECRUITINGPHASE3NCT06093672Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia VeraItalfarmaco
- RECRUITINGPHASE1NCT06752746A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia VeraMabwell (Shanghai) Bioscience Co., Ltd.
- RECRUITINGPHASE2NCT05870475Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PVInstitute of Hematology & Blood Diseases Hospital, China